GSK says RSV vaccine protects against disease over three seasons
WEB2 days ago · The results come from a large Phase 3 trial that supported Arexvy’s approval. Approximately 25,000 people in 17 countries were enrolled in the study, which compared Arexvy to placebo at several time points. Researchers calculated Arexvy’s efficacy against RSV-caused lower respiratory tract disease as 83% during the first season.
GSK RSV shot 43% effective against severe disease in third year
WEB1 day ago · Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the ...
GSK's Arexvy Vaccine Demonstrates Strong Efficacy Against RSV …
WEB1 day ago · GSK has announced promising results for Arexvy, its respiratory syncytial virus (RSV) vaccine, showing a cumulative efficacy of 62.9% against RSV-related lower respiratory tract disease (RSV-LRTD) over three full RSV seasons in adults aged 60 years and older. This vaccine is the only one with efficacy and safety data available through …
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial …
WEB1 day ago · PHILADELPHIA, October 08, 2024--GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial …
WEB1 day ago · Indication for AREXVY. AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 60 years of age and older; Individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
RSV vaccines score landmark FDA approvals - Nature
WEBMay 31, 2023 · GSK’s Arexvy and Pfizer’s Abrysvo provide older adults with a much-needed vaccine for respiratory syncytial virus (RSV) — and raise hopes for an option for infants too.
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time. The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy ...